March 24, 2025
Update: the Rothschild-guided potential sale of Swiss Rivopharm, a privately-owned niche pharmaco and CDMO firm, may come back this year as the Q3-2024 process did not materialize, acc. to sources (NKP | M&A Insights Proprietary)
NKP | M&A Insights Proprietary
Headline from pre-deal coverage in M&A Insights